Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study
BackgroundDiabetes, a chronic disease necessitating long-term treatment and self-management, presents significant challenges for patients who spend most of their treatment time outside of hospitals. The potential of digital therapeutics for diabetes has garnered recognition f...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2025-01-01
|
| Series: | Journal of Medical Internet Research |
| Online Access: | https://www.jmir.org/2025/1/e67554 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841542627287105536 |
|---|---|
| author | Chenxi Li Lixin Guo Lixin Shi Li Chen Liming Chen Yaoming Xue Hong Li Yuzhen Liang Jing Yang Weimin Wang Dalong Zhu |
| author_facet | Chenxi Li Lixin Guo Lixin Shi Li Chen Liming Chen Yaoming Xue Hong Li Yuzhen Liang Jing Yang Weimin Wang Dalong Zhu |
| author_sort | Chenxi Li |
| collection | DOAJ |
| description |
BackgroundDiabetes, a chronic disease necessitating long-term treatment and self-management, presents significant challenges for patients who spend most of their treatment time outside of hospitals. The potential of digital therapeutics for diabetes has garnered recognition from different organizations. Although some prior studies have demonstrated successful reductions in patients’ blood glucose levels and body weight through digital diabetes programs, many studies were limited by including patients with prediabetes, including patients treated with mostly premixed insulin, or evaluating user engagement outcomes rather than clinical outcomes. Consequently, limited evidence remains regarding the effectiveness of health management mobile apps specifically designed for patients with type 2 diabetes mellitus (T2DM) initiating basal insulin (BI). Based on this, a data-based and artificial intelligence management system named “TRIO” was developed to provide patients with more personalized intervention methods in stages, in groups, and around the clock. TRIO assists doctors and nurses in achieving better blood glucose controls, truly carries out standardized management around patients, and allows them to have a higher quality of life. TRIO represents the 3 essential pillars in comprehensive diabetes management: physician, nurse, and patient.
ObjectiveThis prospective observational study evaluated the effectiveness and safety of the TRIO optimal health management program for patients with T2DM initiating BI therapy in a real-world setting.
MethodsPatients aged 18-85 years with inadequate glycemic control (baseline hemoglobin A1c [HbA1c] ≥7%) starting BI therapy were enrolled in outpatient and inpatient settings. The study lasted 3 months, with health education and phone-based follow-up assessments. Data collected included patient characteristics, medical history, baseline diabetes conditions, treatment compliance, glycemic control, and safety indicators.
ResultsA total of 199,431 patients were included, and 118,134 patients completed the 3-month follow-up between December 1, 2019, and December 31, 2021, involving 574 hospitals in China. The mean baseline HbA1c was 9.2%, the mean duration of diabetes was 7.3 years, and 80.4% (1,59,930/1,98,969) of patients were using BI with oral antihyperglycemic drugs. After the intervention, mean HbA1c decreased by –2.59% from baseline, with 55.6% (28,858/51,912) achieving the target HbA1c level of <7%. Patients who set lower fasting plasma glucose goals (<6.1 mmol/L) showed more significant HbA1c reductions (P<.001) and higher target achievement than those with fasting plasma glucose goals of ≥6.1 mmol/L. Factors such as complications, diabetes duration, and baseline HbA1c levels influenced the magnitude of HbA1c reduction. The presence of complications, shorter diabetes duration, and higher baseline HbA1c were significantly associated with increased hypoglycemia incidence risk (all P<.05).
ConclusionsThe TRIO optimal health management program effectively improved glycemic control in patients with T2DM initiating BI therapy. Individualized treatment approaches considering patient characteristics and glycemic goals are vital for optimal outcomes. |
| format | Article |
| id | doaj-art-b1c04dd541a440789eb1ae780e4be5e3 |
| institution | Kabale University |
| issn | 1438-8871 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | Journal of Medical Internet Research |
| spelling | doaj-art-b1c04dd541a440789eb1ae780e4be5e32025-01-13T21:00:57ZengJMIR PublicationsJournal of Medical Internet Research1438-88712025-01-0127e6755410.2196/67554Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World StudyChenxi Lihttps://orcid.org/0000-0001-7489-7234Lixin Guohttps://orcid.org/0000-0003-2596-8387Lixin Shihttps://orcid.org/0000-0002-0389-2732Li Chenhttps://orcid.org/0000-0001-7670-8062Liming Chenhttps://orcid.org/0000-0001-6171-3432Yaoming Xuehttps://orcid.org/0000-0002-3570-1099Hong Lihttps://orcid.org/0000-0002-0284-2282Yuzhen Lianghttps://orcid.org/0000-0002-1958-5024Jing Yanghttps://orcid.org/0000-0001-8855-6254Weimin Wanghttps://orcid.org/0000-0002-8843-131XDalong Zhuhttps://orcid.org/0000-0002-1064-1261 BackgroundDiabetes, a chronic disease necessitating long-term treatment and self-management, presents significant challenges for patients who spend most of their treatment time outside of hospitals. The potential of digital therapeutics for diabetes has garnered recognition from different organizations. Although some prior studies have demonstrated successful reductions in patients’ blood glucose levels and body weight through digital diabetes programs, many studies were limited by including patients with prediabetes, including patients treated with mostly premixed insulin, or evaluating user engagement outcomes rather than clinical outcomes. Consequently, limited evidence remains regarding the effectiveness of health management mobile apps specifically designed for patients with type 2 diabetes mellitus (T2DM) initiating basal insulin (BI). Based on this, a data-based and artificial intelligence management system named “TRIO” was developed to provide patients with more personalized intervention methods in stages, in groups, and around the clock. TRIO assists doctors and nurses in achieving better blood glucose controls, truly carries out standardized management around patients, and allows them to have a higher quality of life. TRIO represents the 3 essential pillars in comprehensive diabetes management: physician, nurse, and patient. ObjectiveThis prospective observational study evaluated the effectiveness and safety of the TRIO optimal health management program for patients with T2DM initiating BI therapy in a real-world setting. MethodsPatients aged 18-85 years with inadequate glycemic control (baseline hemoglobin A1c [HbA1c] ≥7%) starting BI therapy were enrolled in outpatient and inpatient settings. The study lasted 3 months, with health education and phone-based follow-up assessments. Data collected included patient characteristics, medical history, baseline diabetes conditions, treatment compliance, glycemic control, and safety indicators. ResultsA total of 199,431 patients were included, and 118,134 patients completed the 3-month follow-up between December 1, 2019, and December 31, 2021, involving 574 hospitals in China. The mean baseline HbA1c was 9.2%, the mean duration of diabetes was 7.3 years, and 80.4% (1,59,930/1,98,969) of patients were using BI with oral antihyperglycemic drugs. After the intervention, mean HbA1c decreased by –2.59% from baseline, with 55.6% (28,858/51,912) achieving the target HbA1c level of <7%. Patients who set lower fasting plasma glucose goals (<6.1 mmol/L) showed more significant HbA1c reductions (P<.001) and higher target achievement than those with fasting plasma glucose goals of ≥6.1 mmol/L. Factors such as complications, diabetes duration, and baseline HbA1c levels influenced the magnitude of HbA1c reduction. The presence of complications, shorter diabetes duration, and higher baseline HbA1c were significantly associated with increased hypoglycemia incidence risk (all P<.05). ConclusionsThe TRIO optimal health management program effectively improved glycemic control in patients with T2DM initiating BI therapy. Individualized treatment approaches considering patient characteristics and glycemic goals are vital for optimal outcomes.https://www.jmir.org/2025/1/e67554 |
| spellingShingle | Chenxi Li Lixin Guo Lixin Shi Li Chen Liming Chen Yaoming Xue Hong Li Yuzhen Liang Jing Yang Weimin Wang Dalong Zhu Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study Journal of Medical Internet Research |
| title | Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study |
| title_full | Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study |
| title_fullStr | Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study |
| title_full_unstemmed | Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study |
| title_short | Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study |
| title_sort | effectiveness and safety of the trio optimal health management program in patients with type 2 diabetes mellitus initiating basal insulin therapy prospective observational real world study |
| url | https://www.jmir.org/2025/1/e67554 |
| work_keys_str_mv | AT chenxili effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT lixinguo effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT lixinshi effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT lichen effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT limingchen effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT yaomingxue effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT hongli effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT yuzhenliang effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT jingyang effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT weiminwang effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy AT dalongzhu effectivenessandsafetyofthetriooptimalhealthmanagementprograminpatientswithtype2diabetesmellitusinitiatingbasalinsulintherapyprospectiveobservationalrealworldstudy |